NovaBridge Biosciences (NBP) Discusses Phase 2a Clinical Data and Development Plan for VIS-101 in Wet Age-Related Macular Degeneration Transcript
Source: SeekingAlpha
2026-03-09 15:27:59 ET
NovaBridge Biosciences (NBP) Discusses Phase 2a Clinical Data and Development Plan for VIS-101 in Wet Age-Related Macular Degeneration March 9, 2026 9:00 AM EDT...
Read the full article on Seeking Alpha
For further details see:
NovaBridge Biosciences (NBP) Discusses Phase 2a Clinical Data and Development Plan for VIS-101 in Wet Age-Related Macular Degeneration Transcript
NovaBridge Biosciences Sponsored ADS
NASDAQ: NBP
NBP Trading
-4.97% G/L:
$3.44 Last:
861,993 Volume:
$3.40 Open:
NBP Latest News
March 09, 2026 07:00:00 am
NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study
March 03, 2026 09:05:40 am
NovaBridge to Host Business Update Call to Review Phase 2a Data for VIS-101 in Wet AMD on Monday, March 9, 2026
March 02, 2026 07:00:00 am
NovaBridge to Present at the Leerink Partners 2026 Global Healthcare Conference
NBP Stock Data
$393,278,372
87,740,175
N/A
14
N/A
Biotechnology & Life Sciences
Healthcare
US
Rockville
